JP4036885B2 - キナゾリン誘導体 - Google Patents

キナゾリン誘導体 Download PDF

Info

Publication number
JP4036885B2
JP4036885B2 JP2006526686A JP2006526686A JP4036885B2 JP 4036885 B2 JP4036885 B2 JP 4036885B2 JP 2006526686 A JP2006526686 A JP 2006526686A JP 2006526686 A JP2006526686 A JP 2006526686A JP 4036885 B2 JP4036885 B2 JP 4036885B2
Authority
JP
Japan
Prior art keywords
formula
quinazoline
chloro
oxy
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006526686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505875A (ja
JP2007505875A5 (enExample
Inventor
ブラッドベリー，ロバート・ヒュー
ヘンネキン，ローラン・フランソワ・アンドレ
バーラーム，ベルナルド・クリストフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007505875A publication Critical patent/JP2007505875A/ja
Publication of JP2007505875A5 publication Critical patent/JP2007505875A5/ja
Application granted granted Critical
Publication of JP4036885B2 publication Critical patent/JP4036885B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006526686A 2003-09-19 2004-09-15 キナゾリン誘導体 Expired - Fee Related JP4036885B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03292309 2003-09-19
EP04291248 2004-05-14
PCT/GB2004/003937 WO2005028469A1 (en) 2003-09-19 2004-09-15 Quinazoline derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007240846A Division JP2008037874A (ja) 2003-09-19 2007-09-18 キナゾリン誘導体

Publications (3)

Publication Number Publication Date
JP2007505875A JP2007505875A (ja) 2007-03-15
JP2007505875A5 JP2007505875A5 (enExample) 2007-07-05
JP4036885B2 true JP4036885B2 (ja) 2008-01-23

Family

ID=34379392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006526686A Expired - Fee Related JP4036885B2 (ja) 2003-09-19 2004-09-15 キナゾリン誘導体
JP2007240846A Pending JP2008037874A (ja) 2003-09-19 2007-09-18 キナゾリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007240846A Pending JP2008037874A (ja) 2003-09-19 2007-09-18 キナゾリン誘導体

Country Status (32)

Country Link
US (2) US8318752B2 (enExample)
EP (1) EP1667992B1 (enExample)
JP (2) JP4036885B2 (enExample)
KR (1) KR101262442B1 (enExample)
CN (1) CN1882569B (enExample)
AR (1) AR045762A1 (enExample)
AT (1) ATE352550T1 (enExample)
AU (1) AU2004274227B2 (enExample)
BR (1) BRPI0414532B1 (enExample)
CA (1) CA2538752C (enExample)
CO (1) CO5680435A2 (enExample)
CY (1) CY1106405T1 (enExample)
DE (1) DE602004004553T2 (enExample)
DK (1) DK1667992T3 (enExample)
ES (1) ES2279441T3 (enExample)
HR (1) HRP20070113T3 (enExample)
IL (1) IL174284A (enExample)
IS (1) IS2545B (enExample)
MX (1) MXPA06003113A (enExample)
MY (1) MY138851A (enExample)
NO (1) NO333904B1 (enExample)
NZ (1) NZ545913A (enExample)
PL (1) PL1667992T3 (enExample)
PT (1) PT1667992E (enExample)
RU (1) RU2370494C2 (enExample)
SA (1) SA04250296B1 (enExample)
SI (1) SI1667992T1 (enExample)
TW (1) TWI342879B (enExample)
UA (1) UA83252C2 (enExample)
UY (1) UY28522A1 (enExample)
WO (1) WO2005028469A1 (enExample)
ZA (1) ZA200602264B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
AU2004272348B2 (en) 2003-09-16 2008-09-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DK1667992T3 (da) 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005075439A1 (en) 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
DE602005026865D1 (de) * 2004-12-14 2011-04-21 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
US8735410B2 (en) * 2005-02-26 2014-05-27 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
WO2006119674A1 (en) * 2005-05-12 2006-11-16 Wenlin Huang The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
WO2007029251A2 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
CA2631813A1 (en) * 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
BRPI0807234A2 (pt) 2007-02-06 2014-06-03 Boehringer Ingelheim Int Heterociclos bicíclicos, composições farmacêuticas que contêm estes compostos, o uso dos mesmos e processos para a preparação dos mesmos
PT2245026E (pt) 2008-02-07 2012-10-15 Boehringer Ingelheim Int Heterociclos espirocíclicos, produtos farmacêuticos contendo estes compostos, sua utilização e processo para a sua preparação
WO2009138779A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
WO2009138780A2 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Therapeutic treatment - 355
US8088782B2 (en) * 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
AU2010240717A1 (en) * 2009-04-23 2011-10-27 Astrazeneca Ab Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1- (N-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline
CN102060875B (zh) * 2009-11-18 2014-03-12 天津药物研究院 喹唑啉衍生物、制备方法和用途
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CN103012368A (zh) * 2011-09-22 2013-04-03 北大方正集团有限公司 喹啉衍生物
CN103012367A (zh) * 2011-09-22 2013-04-03 北大方正集团有限公司 一种喹啉衍生物
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
RS56566B1 (sr) 2013-03-06 2018-02-28 Astrazeneca Ab Inhibitori hinazolina aktivirajućih mutantnih oblika receptora epidermalnog faktora rasta
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
ES2775614T3 (es) 2015-03-20 2020-07-27 Chai Tai Tianqing Pharmaceutical Group Co Ltd Sales de derivado de quinazolina y método de preparación de las mismas
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
CN114867719B (zh) 2019-11-06 2024-06-25 柳韩洋行 吡咯烷和哌啶化合物

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985749A (en) 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4332420A (en) 1980-01-11 1982-06-01 Coski William D Reciprocably supported dual drive member and features thereof
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4921863A (en) 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JPH0436885A (ja) * 1990-05-31 1992-02-06 Sharp Corp 光学式文字読取装置
US5252586A (en) 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
DE4105503A1 (de) 1991-02-19 1992-08-20 Jenapharm Gmbh Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkoemmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte fuer dieses verfahren
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
PL180336B1 (pl) 1993-05-26 2001-01-31 Syntex Inc Nowe 1-fenyloalkanony, bedace ligandami receptorów 5-HT, kompozycja farmaceutyczna zawierajaca 1-fenyloalkanony i sposób otrzymywania 1-fenyloalkanonów PL PL PL PL PL
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ID18666A (id) 1996-01-31 1998-04-30 Gist Brocades Bv Penggunaan komposisi komposisi yang terdiri dari senyawa senyawa stabil yang efektif secara biologi
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
US6004967A (en) 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
GB9626589D0 (en) 1996-12-20 1997-02-05 Prolifix Ltd Peptides
US5929080A (en) 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
JP4245682B2 (ja) 1997-12-25 2009-03-25 協和発酵キリン株式会社 キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
US6384223B1 (en) 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
ID29800A (id) 1999-02-27 2001-10-11 Boehringer Ingelheim Pharma Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU4145200A (en) 1999-05-07 2000-11-21 Takeda Chemical Industries Ltd. Cyclic compounds and uses thereof
US6126917A (en) 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
PT1731511E (pt) 1999-06-21 2015-11-13 Boehringer Ingelheim Pharma Heterociclos bicíclicos, medicamentos contendo estes compostos, a sua utilização e processos para a sua preparação
EP1216228B1 (en) 1999-09-17 2008-10-29 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20030152572A1 (en) 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
US20040110743A1 (en) 2000-05-19 2004-06-10 Masaomi Miyamato -Secretase inhibitors
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US20020082270A1 (en) 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042062A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042060A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
MX240749B (es) 2000-09-01 2006-10-04 Fmc Corp Bencenos disubstituidos-1,4 en la forma de insecticidas.
WO2002020020A1 (en) 2000-09-08 2002-03-14 Pharmacia Italia S.P.A. Exemestane as chemopreventing agent
WO2002030358A2 (en) 2000-10-11 2002-04-18 Tularik Inc. Modulation of ccr4 function
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
CA2427184A1 (en) * 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
KR20040025881A (ko) 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 개선된 흡수성을 갖는 의약 조성물
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
EP1369418B1 (en) 2001-02-21 2010-07-28 Mitsubishi Tanabe Pharma Corporation Quinazoline derivatives
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
AU2002342051B2 (en) 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
JP2003246780A (ja) 2001-12-17 2003-09-02 Eisai Co Ltd 含窒素芳香環化合物の製造方法
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
EP1481971B1 (en) 2002-02-06 2011-11-16 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2003082290A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4- ( n-phenylamino ) -chinazoline/chinoline als tyrosinkinaseinhibitoren
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
US20060002934A1 (en) 2002-05-15 2006-01-05 Birgit Luber Egf receptor antagonists in the treatment of gastric cancer
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
US20050148607A1 (en) 2002-06-03 2005-07-07 Tsuyoshi Suzuki Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr
WO2004006846A2 (en) 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
AU2003256783A1 (en) 2002-07-25 2004-02-16 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
WO2004013091A2 (en) 2002-08-01 2004-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
JPWO2004060400A1 (ja) 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
DE10300098A1 (de) 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
DE10300097A1 (de) 2003-01-07 2004-07-22 Bayer Ag Kupfer-Komplexe und ihre Verwendung
NZ542153A (en) 2003-02-10 2009-01-31 Vertex Pharma Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
JP2007517767A (ja) 2003-03-11 2007-07-05 ダナ ファーバー キャンサー インスティテュート ウイルスの病原性の阻害方法
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN1972712A (zh) 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
KR20060054388A (ko) 2003-07-29 2006-05-22 아스트라제네카 아베 티로신 키나아제 억제제로서의 피페리딜-퀴나졸린 유도체
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
JP2007502807A (ja) 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
DK1667992T3 (da) 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
DE602004004811T2 (de) 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
WO2005030757A1 (en) 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
CN105106199A (zh) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法

Also Published As

Publication number Publication date
ES2279441T3 (es) 2007-08-16
MXPA06003113A (es) 2006-06-20
CN1882569A (zh) 2006-12-20
MY138851A (en) 2009-08-28
RU2006112845A (ru) 2007-11-10
AU2004274227B2 (en) 2008-04-24
NO333904B1 (no) 2013-10-14
NZ545913A (en) 2009-01-31
EP1667992B1 (en) 2007-01-24
JP2008037874A (ja) 2008-02-21
PL1667992T3 (pl) 2007-05-31
IS8412A (is) 2006-04-12
AR045762A1 (es) 2005-11-09
DE602004004553T2 (de) 2007-10-25
HRP20070113T3 (en) 2007-04-30
IL174284A (en) 2014-09-30
IS2545B (is) 2009-10-15
KR101262442B1 (ko) 2013-05-08
US20120329795A1 (en) 2012-12-27
US8318752B2 (en) 2012-11-27
RU2370494C2 (ru) 2009-10-20
KR20060089742A (ko) 2006-08-09
TWI342879B (en) 2011-06-01
DK1667992T3 (da) 2007-04-30
JP2007505875A (ja) 2007-03-15
SI1667992T1 (sl) 2007-06-30
SA04250296B1 (ar) 2008-07-14
WO2005028469A1 (en) 2005-03-31
CA2538752A1 (en) 2005-03-31
NO20061327L (no) 2006-04-05
ZA200602264B (en) 2007-12-26
HK1091489A1 (en) 2007-01-19
UA83252C2 (uk) 2008-06-25
IL174284A0 (en) 2006-08-01
CO5680435A2 (es) 2006-09-29
CY1106405T1 (el) 2011-10-12
UY28522A1 (es) 2005-04-29
EP1667992A1 (en) 2006-06-14
AU2004274227A1 (en) 2005-03-31
CN1882569B (zh) 2010-09-29
BRPI0414532B1 (pt) 2018-06-05
PT1667992E (pt) 2007-04-30
TW200526629A (en) 2005-08-16
DE602004004553D1 (de) 2007-03-15
ATE352550T1 (de) 2007-02-15
US20080096881A1 (en) 2008-04-24
BRPI0414532A (pt) 2006-11-07
CA2538752C (en) 2011-08-02

Similar Documents

Publication Publication Date Title
JP4036885B2 (ja) キナゾリン誘導体
CN1882570B (zh) 喹唑啉衍生物
US7148230B2 (en) Quinazoline derivatives
US20070099943A1 (en) Quinazoline derivatives
KR20060095767A (ko) 항증식제로서의 퀴나졸린 유도체
CN101659658B (zh) 氰基取代的喹啉衍生物
CN101659657B (zh) 氰基取代的喹啉衍生物及其制备方法和用途
HK1091489B (en) Quinazoline derivatives
HK1091486B (en) Quinazoline derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070517

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20070517

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20070612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070920

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071030

R150 Certificate of patent or registration of utility model

Ref document number: 4036885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101109

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111109

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121109

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121109

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131109

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees